Disclosure for John Hughes

Dr Hughes is currently employed by The University of Vermont and Fletcher Allen Health Care. Since 7/1/2007, he has received research grants from the National Institute on Health, Pfizer; the later two develops and sells smoking cessation medications. During this time, he has accepted honoraria or consulting fees from several non-profit and for-profit organizations and companies that develop, sell or promote smoking cessation products or services or educate/advocate about smoking cessation: Abbot Pharmaceuticals; Acrux; Aradigm; American Academy of Addiction Psychiatry; American Psychiatric Association; Begbies Traynor; Cambridge Hospital, Cline, Davis and Mann; Constella Group; Consultants in Behavior Change; Dean Foundation, DLA Piper, EPI-Q, European Respiratory Society, Evotec; Exchange Limited; Fagerstrom Consulting; Free and Clear; Glaxo-Smith Kline; Golin Harris; Healthwise; Insyght; Informed, Invivodata; Johns Hopkins University; J L Reckner;, Maine Medical Center; McGill University Medical School, McNeil Pharmaceuticals; Novartis Pharmaceuticals; Oglivy Health PR, Ottawa Heart Institute, Pfizer Pharmaceuticals; Pinney Associates; Propagate Pharmaceuticals. Reuters; Scientia, Selecta; Temple University of Health Sciences; University of Arkansas; University of California-San Francisco; University of Cantabria; University of Kentucky, University of New Mexico, US National Institutes on Health; Wolters Publishing, and Xenova.

Last modified December 01 2010 10:28 AM